Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Synthesis and biological evaluation of novel peripherally active morphiceptin analogs
Karlstads universitet, Fakulteten för teknik- och naturvetenskap, Avdelningen för kemi och biomedicinsk vetenskap.
Vise andre og tillknytning
2010 (engelsk)Inngår i: Peptides, ISSN 0196-9781, Vol. 31, nr 8, s. 1617-1624Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Morphiceptin (Tyr-Pro-Phe-Pro-NH2), a tetrapeptide present in the enzymatic digest of bovine beta-casein,is a selective ligand of the mu-opioid receptor. In the present study, we describe the synthesis of a series of novel morphiceptin analogs modified in positions 13. Two of the obtained analogs, [Dmt1, d-Ala2, d-1-Nal3]morphiceptin and [Dmt1, d-NMeAla2, d-1-Nal3]morphiceptin (Dmt2,6-dimethyltyrosine andd-1-Nal3-(1-naphthyl)-d-alanine)) displayed very high -receptor affinity, resistance to enzymaticdegradation, and remarkable supraspinally mediated analgesia, as shown in the hot-plate test afterintracerebroventricular but not intravenous administration, which indicated that they could not cross the bloodbrain barrier. Therefore, these two analogs were further tested in vitro and in vivo towards their possible peripheral analgesic activity and inhibitory effect on gastrointestinal (GI) motility.Wereport that both peptides showed strong antinociceptive effect in the writhing test after intraperitoneal administration, inhibited smooth muscle contractility in vitro and GI motility in vivo. Taken together, these findings indicate that the novel morphiceptin analogs which induce peripheral, but not central antinociception,inhibit GI transit, and possess exceptional metabolic stability, may provide an interesting approach to the development of peripherally restricted agents for the treatment of GI motility disorders, such as diarrhea or diarrhea-predominant irritable bowel syndrome

sted, utgiver, år, opplag, sider
Amsterdam: Elsevier , 2010. Vol. 31, nr 8, s. 1617-1624
HSV kategori
Forskningsprogram
Biomedicin
Identifikatorer
URN: urn:nbn:se:kau:diva-10571DOI: 10.1016/j.peptides.2010.04.018OAI: oai:DiVA.org:kau-10571DiVA, id: diva2:494114
Tilgjengelig fra: 2012-02-08 Laget: 2012-02-08 Sist oppdatert: 2015-06-25bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fullteksthttp://www.ncbi.nlm.nih.gov/pubmed/20434497http://www.sciencedirect.com.ezproxy.ub.gu.se/science?_ob=MImg&_imagekey=B6T0M-4YYRMFF-1-K&_cdi=4866&_user=646099&_pii=S0196978110001725&_origin=browse&_zone=rslt_list_item&_coverDate=08%2F31%2F2010&_sk=999689991&wchp=dGLbVtz-zSkzV&md5=8fdeb53da876738b9e3

Personposter BETA

Delbro, Dick

Søk i DiVA

Av forfatter/redaktør
Delbro, Dick
Av organisasjonen

Søk utenfor DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric

doi
urn-nbn
Totalt: 30 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf